Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of PD1-TIL and TIL in Glioblastoma
NCT03347097Phase 1Unknown
- Sponsor
- Huashan Hospital
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of PD1-TIL in glioblastoma multiforme (GBM) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Number of Adverse Events related to TIL and PD1-TIL cells infusion at 1 month. Status: unknown.
02
Drugs
PD1-TIL
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT03347097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347097.